title: Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation.
abstract: Allogeneic bone marrow transplantation (BMT) is the only curative therapy available for patients with myelodysplastic syndrome (MDS). In an attempt to identify prognostic factors influencing outcome, we collected data retrospectively on 60 consecutive adult patients who had undergone BMT at our center for primary MDS or acute myelogenous leukemia evolving from preexisting primary MDS (sAML). Patients were divided into subgroups according to cytogenetic abnormalities based on a recently described International MDS Workshop categorization system. The 7-year actuarial event-free survival (EFS), relapse rate, and nonrelapse mortality (NRM) for all patients were 29% (95% confidence interval [CI], 16% to 43%), 42% (CI, 24% to 67%), and 50% (CI, 37% to 64%), respectively. The EFS for the good-, intermediate-, and poor-risk cytogenetic subgroups were 51% (CI, 30% to 69%), 40% (CI, 16% to 63%), and 6% (CI, 0% to 24%), respectively (P = .003). The corresponding actuarial relapse rates were 19% (CI, 6% to 49%), 12% (CI, 2% to 61%), and 82% (CI, 48% to 99%), respectively (P = . 002) with no difference in NRM between the subgroups. Univariate analysis showed cytogenetic category, French-American-British (FAB) subtype, and graft-versus-host disease (GVHD) prophylaxis used to be predictive of relapse and EFS. In multivariate analysis, only the cytogenetic category was predictive of EFS, with the relative risk of treatment failure for the good-, intermediate-, and poor-risk cytogenetic subgroups being 1.0, 1.5, and 3.5, respectively (P = . 004). For adults with primary MDS and sAML, even after BMT, poor-risk cytogenetics are predictive of an unfavorable outcome; novel treatment strategies will be required to improve results with allogeneic BMT in this patient population.
authors.affiliation: The Leukemia and Bone Marrow Transplantation Program of British Columbia, the Divisions of Hematology and Laboratory Medicine, British Columbia Cancer Agency, Vancouver Hospital and Health Sciences Centre, Canada.
authors.forename: T J
authors.initials: TJ
authors.lastname: Nevill
authors.forename: H C
authors.initials: HC
authors.lastname: Fung
authors.forename: J D
authors.initials: JD
authors.lastname: Shepherd
authors.forename: D E
authors.initials: DE
authors.lastname: Horsman
authors.forename: S H
authors.initials: SH
authors.lastname: Nantel
authors.forename: H G
authors.initials: HG
authors.lastname: Klingemann
authors.forename: D L
authors.initials: DL
authors.lastname: Forrest
authors.forename: C L
authors.initials: CL
authors.lastname: Toze
authors.forename: H J
authors.initials: HJ
authors.lastname: Sutherland
authors.forename: D E
authors.initials: DE
authors.lastname: Hogge
authors.forename: S C
authors.initials: SC
authors.lastname: Naiman
authors.forename: A
authors.initials: A
authors.lastname: Le
authors.forename: D A
authors.initials: DA
authors.lastname: Brockington
authors.forename: M J
authors.initials: MJ
authors.lastname: Barnett
mesh_terms: D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation / Q000379:methods*; D002869:Chromosome Aberrations / Q000235:genetics; D025063:Chromosome Disorders; D018572:Disease-Free Survival; D005260:Female; D006086:Graft vs Host Disease / Q000517:prevention & control; D006801:Humans; D007621:Karyotyping; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000175:diagnosis / Q000235:genetics* / Q000628:therapy*; D011379:Prognosis; D012008:Recurrence; D012307:Risk Factors; D019172:Transplantation Conditioning / Q000379:methods*; D014184:Transplantation, Homologous; D016896:Treatment Outcome